New combo aims to tackle tough breast cancer
NCT ID NCT07040644
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests whether combining the targeted chemotherapy sacituzumab govitecan with the immunotherapy toripalimab works better than toripalimab plus standard chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer that is PD-L1 positive. About 150 participants will be randomly assigned to one of the two treatment groups. The main goal is to see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sacituzumab govitecan (a targeted chemotherapy) and toripalimab (an immunotherapy), compared with toripalimab plus nab-paclitaxel (a standard chemotherapy)
- What this could lead to
- If this works, it could offer a more effective first-line treatment option for people with advanced triple-negative breast cancer that is PD-L1 positive.
- What could go wrong
- This is a phase 2 trial with only 150 participants, so results are preliminary. The combination may not improve survival and could cause side effects like immune reactions or low blood cell counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510120, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
- Freezing tumors to supercharge immunotherapy: new hope for aggressive breast cancer?
- New antibody drug aims to unleash immune system on Hard-to-Treat cancers
- Immunotherapy avelumab aims to stop triple negative breast cancer recurrence
- New drug combo takes on advanced cancers in early trial
- New drug combo aims to keep advanced breast cancer in check